- Home
- AIRS vs IXHL Comparison
AIRS vs IXHL Comparison
Compare AIRS & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIRS | IXHL |
|---|---|---|
| Founded | 2012 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.3M | 134.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | AIRS | IXHL |
|---|---|---|
| Price | $2.88 | $0.31 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.75 | N/A |
| AVG Volume (30 Days) | 1.6M | ★ 7.2M |
| Earning Date | 03-13-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $157,554,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.53 | $0.08 |
| 52 Week High | $12.00 | $2.25 |
Technical Indicators
Market Signals| Indicator | AIRS | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 30.86 |
| Support Level | $2.15 | $0.34 |
| Resistance Level | $3.15 | $0.37 |
| Average True Range (ATR) | 0.35 | 0.02 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 63.89 | 3.89 |
Price Performance
Historical ComparisonAbout AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.